Pre-clinical studies
The pre-clinical trial is crucial when transitioning to the clinical stage.
Primo offers a service platform for pre-clinical trials on animals and medical imaging.
The platform provides trials and evaluation for new medical development.For animal trials, there are two common models. Allogeneic model and xenograft model. The allogeneic model is best for research on the relationship between tumor metabolism and the immune system. The xenograft model implants human tissue-derived cells into immunodeficient animal models to evaluate the efficacy of medicine and treatment with regards to tumor progression.
Primo also offers a bioluminescence filter platform to detect the reaction of cells and hosts, to track molecular imaging performance during the preclinical stage.
The orthotopic model helps to establish a tumor development model for the in vivo image system (IVIS). It coworks with small animal positron emission tomography (PET), computer tomography (CT), and microPET/CT to provide early-stage cell imaging without bioluminescence performance.
Based on molecular imaging systems, the targeted cell can be precisely located for further treatment.
The modern organoid model has developed over time. As it maintains the function of the original organs and simulates the environment of targeted body organs, the organoid model is expected to replace traditional animal trials. Speeding up development and lowering research costs have been notable trends. Primo has successfully established tumoroid/organoid models for a future high throughput screening (HTS) platform.
Pre-clinical medicine combination and drug-concentration evaluation
Collecting tumor organoids (tumoroids) clinically also helps build up patient-derived organoid xenografts. PDOX models, including chorioallantoic membrane (CAM model) for a short-term drug screening platform for ex vivo. Eventually this provides trial and evaluation for pre-clinical medical combinations and favorable drug-concentration.
Integrating pre-clinical trial platforms leads to possibilities and opportunities for new and more modern medical technologies.
Primo integrates clinical and academic experiences and advantages to enhance domestic medical competence and aim at international influence. We utilize advanced preclinical animal trial platforms for accurate evaluation. Primo also specializes in combining lab-on-chip and high-throughput screening (HTS) to speed up the process of drug development and significantly increase treatment efficacy through customized metabolomics analysis.
Preclinical animal monitoring platform
The orthotopic model not only provides drug trials but also helps develop preclinical animal trial screening platforms to monitor long-term prognosis monitoring and radiopharmaceutical evaluation.
